Harith Rajagopalan, Fractyl Health CEO
June 23, 2024 01:30 PM EDT
R&D
Cell/Gene Tx

Fractyl pitch­es po­ten­tial of GLP-1 gene ther­a­py, but push­es clin­i­cal tri­als back to 2025

Ryan Cross

Senior Science Correspondent

A small biotech com­pa­ny is de­vel­op­ing a one-time gene ther­a­py that could turn the pan­creas in­to its own GLP-1 drug fac­to­ry and elim­i­nate the need …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times